NASDAQ: TRVNTrevena Inc Stock
$0.68-0.02 (-2.86%)
Updated Mar 20, 2023
TRVN Price
$0.68
Fair Value Price
$3.97
Market Cap
$4.74M
52 Week Low
$0.68
52 Week High
$15.28
P/E
-0.07x
P/B
0.22x
P/S
-62.42x
PEG
N/A
Dividend Yield
N/A
Revenue
-$419.00k
Earnings
-$60.62M
Gross Margin
845.8%
Operating Margin
14,293.79%
Profit Margin
14,467.3%
Debt to Equity
1.33
Operating Cash Flow
-$53M
Beta
0.8
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A
TRVN Overview
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. The company has a collaboration with Imperial College London to evaluate Trv027 in Covid-19 patients. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TRVN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TRVN ($0.68) is undervalued by 82.81% relative to our estimate of its Fair Value price of $3.97 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
TRVN ($0.68) is significantly undervalued by 82.81% relative to our estimate of its Fair Value price of $3.97 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
TRVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more TRVN due diligence checks available for Premium users.
Be the first to know about important TRVN news, forecast changes, insider trades & much more!
TRVN News
Valuation
TRVN fair value
Fair Value of TRVN stock based on Discounted Cash Flow (DCF)
Price
$0.68
Fair Value
$3.97
Undervalued by
82.86%
TRVN ($0.68) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
TRVN ($0.68) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
TRVN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
TRVN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.07x
Industry
16.1x
Market
22.37x
TRVN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.22x
Industry
4.81x
TRVN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TRVN's financial health
Profit margin
Revenue
-$438.0k
Net Income
-$15.3M
Profit Margin
3,492%
TRVN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
TRVN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$51.0M
Liabilities
$29.2M
Debt to equity
1.33
TRVN's short-term assets ($42.54M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TRVN's short-term assets ($42.54M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TRVN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
TRVN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$10.6M
Investing
$12.0M
Financing
$1.1M
TRVN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
TRVN vs Biotech Stocks
Trevena Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.